article thumbnail

Call for a consensual definition of dyslipidemia in coronary angiography trials

Frontiers in Cardiovascular Medicine

We listed definitions and their references in the 258 articles the research found. Out of the 258 articles retrieved in the search, 52 studies (20%) provided a definition of dyslipidemia, and 20 (8%) mentioned the source. A systematic search of coronary angiography studies focusing on dyslipidemia was conducted.

article thumbnail

Finally – the end (of the trial process)

Dr. Malcolm Kendrick

Which is five years and nine months after the articles in the Mail on Sunday were published. And you will note that Barney Calman, the gentleman – and I use this word loosely – who devised and wrote the articles has remained tight lipped. Firstly, the articles were clearly a hatchet job designed to destroy my reputation.

Article 105
article thumbnail

Ezetimibe Plus Statins Equals Better Outcomes

CardiacWire

However, not everyone with high cholesterol benefits from statins, leading many drug developers to focus on novel ways to lower LDL-C levels. Statins are one of the most prescribed drugs in the U.S., with over 25% of all adults 40 and up taking them. of patients with high LDL-C were on ezetimibe.

article thumbnail

LDL Cholesterol Lowering: Is There a Risk for Dementia and Hemorrhagic Stroke?

American College of Cardiology

Reduction in low-density lipoprotein cholesterol (LDL-C) levels has consistently demonstrated a reduced risk of atherosclerotic cardiovascular disease (ASCVD). There is extensive evidence from randomized trials that demonstrates the effectiveness of lipid-lowering agents in reducing ASCVD-related events.

article thumbnail

Harnessing RNA Interference for Cholesterol Lowering: The Bench?to?Bedside Story of Inclisiran

Journal of the American Heart Association

Lowering low‐density lipoprotein cholesterol (LDL‐C) is a cornerstone of reducing risk for atherosclerotic cardiovascular disease. This article reviews the journey of inclisiran from bench to bedside, including early development, the clinical trial program, key characteristics of inclisiran, and practical points for its use in the clinic.

article thumbnail

ACCEL Lite: How Low and How Fast Should We Go with LDL Cholesterol?

American College of Cardiology

Douglas Weaver and Kausik Ray delve into the importance of individualized cholesterol management. In this interview, Drs. They discuss the latest research, the benefits of aggressive LDL reduction, and how tailoring treatment plans can help optimize heart health while minimizing risks.

article thumbnail

We have a judgment (Part 1)

Dr. Malcolm Kendrick

The Mail on Sunday published article(s) that we felt were very damaging and defamatory. In short, we were effectively accused of being liars, and ‘ purveyors of misinformation ’ about statins (drugs that lower LDL/cholesterol). You may remember that he was stuck off as a doctor for his papers and articles on the MMR vaccine.

Article 109